NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR

NF-E2-related factor 2 (NRF2), an antioxidant transcription factor, is activated in autophagy-deficient mice due to the accumulations of p62/SQSTM1 and its subsequent interaction with Kelch-like-ECH-associated protein 1 (KEAP1), an adaptor component for Cullin3-based E3 ubiquitin ligase complex. Far...

Full description

Bibliographic Details
Main Authors: Eun Young Kim, Jae Man Lee
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Antioxidants
Subjects:
Online Access:https://www.mdpi.com/2076-3921/11/2/370
_version_ 1797483180338446336
author Eun Young Kim
Jae Man Lee
author_facet Eun Young Kim
Jae Man Lee
author_sort Eun Young Kim
collection DOAJ
description NF-E2-related factor 2 (NRF2), an antioxidant transcription factor, is activated in autophagy-deficient mice due to the accumulations of p62/SQSTM1 and its subsequent interaction with Kelch-like-ECH-associated protein 1 (KEAP1), an adaptor component for Cullin3-based E3 ubiquitin ligase complex. Farnesoid x receptor (FXR/NR1H4) is a ligand-dependent transcription factor that belongs to the nuclear receptor superfamily. FXR plays an essential role in bile acid synthesis and enterohepatic circulation, affecting glucose and lipid metabolism. Obeticholic acid as a potent FXR agonist has been approved to treat primary biliary cholangitis and clinical trials for its use in the treatment of other liver diseases are underway. Here we show that NRF2 activation in autophagy defects impedes a transactivation of FXR. Liver-specific <i>Atg7</i> knockout mice or a treatment of autophagy inhibitor showed decreased inductions of FXR target genes upon its synthetic agonists. Moreover, enforced NRF2 activations with small molecules potently decreased the pharmacological activation of FXR in cultured cells. Finally, we demonstrate that NRF2 activation by the treatment with the food antioxidant butylated hydroxyanisole is necessary and sufficient to inhibit the pharmacological activation of FXR in vivo. These results reveal a novel function of the basal autophagy-NRF2 axis for the regulation of FXR transactivation, and shed light on a potential therapeutic strategy in metabolic disease.
first_indexed 2024-03-09T22:43:15Z
format Article
id doaj.art-1ce62af8878346f390bb0ccb3717e448
institution Directory Open Access Journal
issn 2076-3921
language English
last_indexed 2024-03-09T22:43:15Z
publishDate 2022-02-01
publisher MDPI AG
record_format Article
series Antioxidants
spelling doaj.art-1ce62af8878346f390bb0ccb3717e4482023-11-23T18:32:45ZengMDPI AGAntioxidants2076-39212022-02-0111237010.3390/antiox11020370NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXREun Young Kim0Jae Man Lee1Department of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, KoreaDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, KoreaNF-E2-related factor 2 (NRF2), an antioxidant transcription factor, is activated in autophagy-deficient mice due to the accumulations of p62/SQSTM1 and its subsequent interaction with Kelch-like-ECH-associated protein 1 (KEAP1), an adaptor component for Cullin3-based E3 ubiquitin ligase complex. Farnesoid x receptor (FXR/NR1H4) is a ligand-dependent transcription factor that belongs to the nuclear receptor superfamily. FXR plays an essential role in bile acid synthesis and enterohepatic circulation, affecting glucose and lipid metabolism. Obeticholic acid as a potent FXR agonist has been approved to treat primary biliary cholangitis and clinical trials for its use in the treatment of other liver diseases are underway. Here we show that NRF2 activation in autophagy defects impedes a transactivation of FXR. Liver-specific <i>Atg7</i> knockout mice or a treatment of autophagy inhibitor showed decreased inductions of FXR target genes upon its synthetic agonists. Moreover, enforced NRF2 activations with small molecules potently decreased the pharmacological activation of FXR in cultured cells. Finally, we demonstrate that NRF2 activation by the treatment with the food antioxidant butylated hydroxyanisole is necessary and sufficient to inhibit the pharmacological activation of FXR in vivo. These results reveal a novel function of the basal autophagy-NRF2 axis for the regulation of FXR transactivation, and shed light on a potential therapeutic strategy in metabolic disease.https://www.mdpi.com/2076-3921/11/2/370autophagynrf2keap1nuclear receptorFXRtransactivation
spellingShingle Eun Young Kim
Jae Man Lee
NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR
Antioxidants
autophagy
nrf2
keap1
nuclear receptor
FXR
transactivation
title NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR
title_full NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR
title_fullStr NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR
title_full_unstemmed NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR
title_short NRF2 Activation in Autophagy Defects Suppresses a Pharmacological Transactivation of the Nuclear Receptor FXR
title_sort nrf2 activation in autophagy defects suppresses a pharmacological transactivation of the nuclear receptor fxr
topic autophagy
nrf2
keap1
nuclear receptor
FXR
transactivation
url https://www.mdpi.com/2076-3921/11/2/370
work_keys_str_mv AT eunyoungkim nrf2activationinautophagydefectssuppressesapharmacologicaltransactivationofthenuclearreceptorfxr
AT jaemanlee nrf2activationinautophagydefectssuppressesapharmacologicaltransactivationofthenuclearreceptorfxr